AEON Biopharma Stock
AEON Biopharma, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Robert Bancroft
- Employees
- 8
- Market cap
- $12 M
- IPO
- 24/07/2023
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in…
AEON Biopharma stock: price history
1D
-4.5%
1W
-15.9%
1M
-9.7%
6M
-77.3%
YTD
-78.9%
1Y
-83.4%
2Y
-99.7%
5Y
–
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~26% weaker price swings than usual
Ask the agents about AEON Biopharma
Analyst assessment of AEON Biopharma
0
STRONG BUY
3
BUY
0
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 01/10/2026
AEON Biopharma stock metrics
P/E
-0.06
P/B
-0.76
EV/EBITDA
-0.43
RETURN ON EQUITY
7.5%
NET MARGIN
0.0%
DEBT/EQUITY
-0.18
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
27.4%
FLOAT SHARES
13,670,408
AVG. DAILY VOLUME (30D)
13,108,453
Insider transactions (SEC)
LYNCH TIMOTHY P
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about AEON Biopharma stock
What does AEON Biopharma do?
AEON Biopharma, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Robert Bancroft, the company employs around 8 people.
The IPO was on 24/07/2023; the stock trades on AMEX under the ticker AEON.
What do analysts say about AEON Biopharma stock?
3 analysts rate the stock, the consensus is Buy (as of 01/10/2026).
This is an external assessment, not a statement by Market Jury.
When does AEON Biopharma report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly -26% stronger than usual.
Does AEON Biopharma pay a dividend?
No, AEON Biopharma currently does not pay a dividend.
Which stocks are comparable to AEON Biopharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get AEON Biopharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess AEON Biopharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.